Barrington Research Reiterates Haemonetics Outperform, $73 PT

Barrington Research reiterated its Haemonetics HAE Outperform rating and $73 price target in a research report published today. In the report, Barrington Research states, "We continue to have confidence in the long-term competitive position of HAE within the blood products industry." Shares of Haemonetics closed today at $64.96, down 0.11% from Monday's market close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsBarrington Research
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!